Inhibition of LOXL2 through genetic method (knockdown of the LOXL2 gene), chemical intervention (using D-penicillamine), or antibody-based targeting of LOXL2 has been shown to markedly diminish the development of distant metastases in an orthotopic model of immunocompromised breast cancer 37. This evidence concerns the gene LOXL2 and breast carcinoma.